Evaluation of the Abelson gene as a control gene for real-time quantitative PCR in multiple myeloma

Abstract

The Abelson (ABL) gene was the best control gene for quantitative PCR (qPCR)-based diagnosis and minimal residual disease detection in leukemic patients. However, there is still no concerted effort focused on the optimization of control genes in multiple myeloma (MM). The results of this study will provide a basis for the use of ABL as a control gene for the quantification of aberrantly expressed genes in MM. We analyzed ABL, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), beta-glucuronidase, and β2-microglobulin genes expression in bone marrow samples of 62 MM patients and 31 healthy donors. MAGE-C1, the most commonly expressed cancer-testis antigen gene in MM, which is to be a potential clinical indicator for auxiliary diagnosis and prognostic evaluation in MM, was also detected. Our experimental results show that the copy numbers of the four control genes were well correlated in all samples detected. The quantitative data for MAGE-C1 using the four control genes also had high correlations. ABL and GAPDH genes were stably expressed in healthy donors and MM patients during therapy and did not vary with disease state. ABL is stable in the MM bone marrow mononuclear fraction, and it could be used as a reliable control gene for the normalization of qPCR studies in MM.